Persantine: Variation in Response Trial



Status:Terminated
Conditions:Peripheral Vascular Disease, Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:21 - Any
Updated:4/17/2018
Start Date:September 2002
End Date:July 2009

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
The primary objective of this study is to understand why different people respond differently
to the medication Persantine. The effects of Persantine will be evaluated by performing
echocardiograms, blood tests and by measuring the flow of blood in the arteries of the heart
in patients undergoing a clinically indicated percutaneous coronary intervention.

Participants will receive three doses of Persantine intravenously for the research study.
Before and after receiving the Persantine doses, patients will have an echocardiogram and
coronary artery blood flow will be measured. Blood tests,measure the function of the
adenosine transporter. In addition variations in the gene for the adenosine transporter will
be evaluated.

Inclusion Criteria:

- Patients > 21 years old

- Patient undergoing cardiac catheterization with planned PTCA or with a significant
coronary lesion of either the LAD or Circumflex

Exclusion Criteria:

- Theophylline or oral Persantine use in 24hrs

- Second or third degree AV block, or sick sinus syndrome without a functioning
pacemaker

- Active asthma or bronchospasm

- Patients with severe hepatic insufficiency

- Patients experiencing an acute transmural infarction at the time of the index visit

- Conditions that are known to affect resistive vessel function or myocardial flow
We found this trial at
1
site
UCONN Health Center
Farmington, Connecticut 06030
?
mi
from
Farmington, CT
Click here to add this to my saved trials